211 related articles for article (PubMed ID: 31167818)
21. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
24. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
[TBL] [Abstract][Full Text] [Related]
25. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Kröger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen YB; Cohen JB; Freytes CO; Gale RP; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Martino R; Mussetti A; Savani BN; Schouten HC; Usmani SZ; Wiernik PH; Wirk B; Smith SM; Sureda A; Hamadani M
Bone Marrow Transplant; 2016 Jan; 51(1):58-66. PubMed ID: 26437062
[TBL] [Abstract][Full Text] [Related]
27. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
[TBL] [Abstract][Full Text] [Related]
28. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
29. [Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-Cell Lymphoma].
Fan D; Liu Q; Xiao F; Guo HX; Zhao H; Yan XQ; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1163-1168. PubMed ID: 34362497
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
Van Den Neste E; Schmitz N; Mounier N; Gill D; Linch D; Trneny M; Bouadballah R; Radford J; Bargetzi M; Ribrag V; Dührsen U; Ma D; Briere J; Thieblemont C; Bachy E; Moskowitz CH; Glass B; Gisselbrecht C
Bone Marrow Transplant; 2017 Feb; 52(2):216-221. PubMed ID: 27643872
[TBL] [Abstract][Full Text] [Related]
31. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Joseph J; Ma J; Hennawy F; Abdulrazzaq MN; Saini N; Patel RD; Hosing CM; Alousi AM; Anderlini P; Popat UR; Qazilbash MH; Shpall EJ; Srour S; Kebriaei P; Bashir Q; Nastoupil LJ; Westin JR; Rondon G; Champlin RE; Andersson BS; Nieto Y; Muzzafar T; Ahmed S
Transplant Cell Ther; 2021 May; 27(5):404.e1-404.e5. PubMed ID: 33965178
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
Epperla N; Hamadani M
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
34. Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study.
Porrata LF; Burgstaler EA; Winters JL; Jacob E; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas J; Paludo J; Markovic SN
Transplant Cell Ther; 2021 Sep; 27(9):769.e1-769.e8. PubMed ID: 34091071
[TBL] [Abstract][Full Text] [Related]
35. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706
[TBL] [Abstract][Full Text] [Related]
36. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.
Izumi K; Kanda J; Nishikori M; Arai Y; Ishikawa T; Yoshioka S; Ueda Y; Maeda T; Yonezawa A; Anzai N; Moriguchi T; Imada K; Akasaka T; Nohgawa M; Itoh M; Aiba A; Tsunemine H; Watanabe M; Kondo T; Takaori-Kondo A
Ann Hematol; 2019 Dec; 98(12):2815-2823. PubMed ID: 31713653
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W
Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828
[TBL] [Abstract][Full Text] [Related]
40. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
